Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page: https://medlineplus.gov/genetics/condition/familial-partial-lipodystrophy/

Familial partial lipodystrophy

Description

Familial partial lipodystrophy is a rare condition that is characterized by the loss of fatty (adipose) tissue that is found underneath the skin (subcutaneous). Affected individuals typically lose subcutaneous adipose tissue from the arms; legs; and the truncal region, which includes the chest, abdomen, and hips. Familial partial lipodystrophy is part of a group of disorders known as lipodystrophies, which can cause the loss of varying amounts of adipose tissue. The severity of familial partial lipodystrophy and the specific signs and symptoms that are seen in affected individuals can vary, even among members of the same family.

Adipose tissue is found in many parts of the body. It stores fat for energy and provides support for the body’s structures. In people with familial partial lipodystrophy, the loss of subcutaneous adipose tissue from the arms, legs, and hips gives these parts of the body a muscular appearance. The fat that is normally stored in these areas builds up in other parts of the body, including the face, neck, and inside the abdomen. This abnormal fat distribution often becomes apparent during childhood or around the time of puberty.

Abnormal fat storage in the body can lead to health problems throughout a person's life. Many people with familial partial lipodystrophy develop insulin resistance, a condition in which the body's tissues cannot adequately respond to insulin. Insulin is a hormone that helps regulate levels of blood glucose, also called blood sugar. Insulin resistance may lead to a condition called diabetes mellitus. People with this condition have high levels of blood glucose.

Additional signs and symptoms of familial partial lipodystrophy can include:

  • A skin condition related to high levels of insulin in which the skin in the folds and creases of the body becomes thick, dark, and velvety (acanthosis nigricans)
  • High levels of fats called triglycerides in the bloodstream (hypertriglyceridemia), which can cause inflammation of the pancreas (acute pancreatitis)
  • An enlarged liver (hepatomegaly) due to an abnormal buildup of fats (hepatic steatosis)

Some affected individuals develop high blood pressure and a buildup of fatty deposits in the arteries (atherosclerosis), which can increase the risk of a form of heart disease called coronary artery disease. After puberty, some women with familial partial lipodystrophy develop signs and symptoms that are likely related to hormonal changes. These can include:

  • Multiple cysts on the ovaries
  • An increased amount of body hair (hirsutism)
  • An inability to conceive (infertility)

There are several forms of familial partial lipodystrophy, which are distinguished by their genetic cause. The most common form is type 2, also called Dunnigan disease. In addition to the signs and symptoms described above, people with familial partial lipodystrophy type 2 may develop:

  • Weakness in the muscles used for movement (skeletal muscles)
  • Abnormalities of the heart muscle (cardiomyopathy)
  • Irregular heartbeats (arrhythmias) 

In people with familial partial lipodystrophy type 2, excess fat may build up around the face, neck, and upper back, especially in women. This appearance is sometimes described as "cushingoid," because it resembles the appearance of people with a hormonal disorder called Cushing syndrome.

Frequency

Familial partial lipodystrophy is a rare disease that affects 1 in 7,000 to 2.3 in 1 million people. However, the exact prevalence is difficult to determine, as many people with this condition likely do not receive a diagnosis. Women tend to receive a diagnosis of familial partial lipodystrophy more often than men. This may be because the loss of fat from the arms, legs, and hips is more easily recognized in women or because complications, such as diabetes mellitus and hypertriglyceridemia, tend to be more severe in women.

Causes

Genetic changes that cause disease are called pathogenic variants. Pathogenic variants in several different genes cause familial partial lipodystrophy. Pathogenic variants in the lamin A/C (LMNA) gene cause familial partial lipodystrophy type 2. The other forms of the disorder are caused by pathogenic variants in other genes.

The LMNA gene provides instructions for making proteins called lamins, which are an important part of the structure that surrounds the nucleus inside cells (the nuclear envelope). Through a mechanism that is not well understood, pathogenic variants in the LMNA gene appear to lead to the premature death of adipocytes, which are the fat-storing cells in adipose tissue. The loss of these cells disrupts the body’s ability to store and use fats properly. This leads to the abnormal distribution of adipose tissue and the resulting health complications that are characteristic of this disorder. Changes in adipose tissue alter hormone production and affect many of the body's organs. However, it is unclear exactly why these changes cause fat to be lost in some parts of the body and abnormally stored in others.

The other genes that are associated with familial partial lipodystrophy provide instructions for making proteins with important roles in fat storage. Specifically, these proteins are necessary for the proper development and function of adipocytes. Pathogenic variants in any of the genes that are associated with familial partial lipodystrophy impair the development, structure, or function of adipocytes and make the body unable to store and use fats properly.

In some people with familial partial lipodystrophy, a pathogenic variant cannot be identified. In these cases, the cause of the disorder is unknown.

Learn more about the genes associated with Familial partial lipodystrophy

Additional Information from NCBI Gene:

Inheritance

Most cases of familial partial lipodystrophy, including type 2, are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In some cases, an affected person inherits the pathogenic variant from a parent. Other cases result from a new (de novo) pathogenic variant in the gene that occurs during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or during early embryonic development. These affected individuals typically have no history of the disorder in their family.

Some types of familial partial lipodystrophy are inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have a pathogenic variant. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Dunnigan-Kobberling syndrome
  • FPL
  • Kobberling-Dunnigan syndrome
  • Lipodystrophy, familial partial

Additional Information & Resources

Genetic Testing Information

Genetic and Rare Diseases Information Center

Patient Support and Advocacy Resources

Clinical Trials

Catalog of Genes and Diseases from OMIM

Scientific Articles on PubMed

References

  • Akinci B, von Schnurbein J, Araujo-Vilar D, Wabitsch M, Oral EA. Lipodystrophy Prevalence, "Lipodystrophy-Like Phenotypes," and Diagnostic Challenges. Diabetes. 2024 Jul 1;73(7):1039-1042. doi: 10.2337/dbi24-0018. No abstract available. Citation on PubMed
  • Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial Partial Lipodystrophy (FPLD): Recent Insights. Diabetes Metab Syndr Obes. 2020 May 6;13:1531-1544. doi: 10.2147/DMSO.S206053. eCollection 2020. Citation on PubMed
  • Bidault G, Vatier C, Capeau J, Vigouroux C, Bereziat V. LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations. Biochem Soc Trans. 2011 Dec;39(6):1752-7. doi: 10.1042/BST20110675. Citation on PubMed
  • Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. doi: 10.1210/jc.2016-2466. Epub 2016 Oct 6. Citation on PubMed
  • Donadille B, Janmaat S, Mosbah H, Belalem I, Lamothe S, Nedelcu M, Jannot AS, Christin-Maitre S, Feve B, Vatier C, Vigouroux C. Diagnostic and referral pathways in patients with rare lipodystrophy and insulin-resistance syndromes: key milestones assessed from a national reference center. Orphanet J Rare Dis. 2024 Apr 27;19(1):177. doi: 10.1186/s13023-024-03173-2. Citation on PubMed
  • Fernandez-Pombo A, Diaz-Lopez EJ, Castro AI, Sanchez-Iglesias S, Cobelo-Gomez S, Prado-Morana T, Araujo-Vilar D. Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review. Cells. 2023 Feb 24;12(5):725. doi: 10.3390/cells12050725. Citation on PubMed
  • Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta. 2009 Jun;1791(6):507-13. doi: 10.1016/j.bbalip.2008.12.014. Epub 2009 Jan 7. Citation on PubMed or Free article on PubMed Central
  • Garg A, Xing C, Agarwal AK, Westfall AK, Tomchick DR, Zhang X, Xing M, Brown RJ. Gain of Function NOTCH3 Variants Cause Familial Partial Lipodystrophy Due to Activation of Senescence Pathways. Diabetes. 2025 Mar 1;74(3):427-438. doi: 10.2337/db24-0624. Citation on PubMed
  • Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011 Nov;96(11):3313-25. doi: 10.1210/jc.2011-1159. Epub 2011 Aug 24. Citation on PubMed
  • Guenantin AC, Briand N, Bidault G, Afonso P, Bereziat V, Vatier C, Lascols O, Caron-Debarle M, Capeau J, Vigouroux C. Nuclear envelope-related lipodystrophies. Semin Cell Dev Biol. 2014 May;29:148-57. doi: 10.1016/j.semcdb.2013.12.015. Epub 2013 Dec 30. Citation on PubMed
  • Hussain I, Garg A. Lipodystrophy Syndromes. Endocrinol Metab Clin North Am. 2016 Dec;45(4):783-797. doi: 10.1016/j.ecl.2016.06.012. Epub 2016 Oct 6. Citation on PubMed
  • Maung JN, Oral EA, MacDougald OA. Lamin A/C in health, laminopathies, and familial partial lipodystrophy 2. Trends Endocrinol Metab. 2026 Mar 17:S1043-2760(26)00010-X. doi: 10.1016/j.tem.2026.01.010. Online ahead of print. Citation on PubMed
  • Rutkowska L, Salachna D, Lewandowski K, Lewinski A, Gach A. Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in PPARG Expanding the Spectrum of Disease-Causing Alterations in FPLD3. Diagnostics (Basel). 2022 Apr 30;12(5):1122. doi: 10.3390/diagnostics12051122. Citation on PubMed
  • Simha V, LoPiccolo MK, Platt A, Brown RJ, Johnson X, Carere DA, Donnelly C, Snyder MT, Xing C, Mathews TP, Gopal P, Ward SC, Tomchick DR, Agarwal AK, DeBerardinis RJ, Garg A. A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia. J Clin Invest. 2025 Nov 4;136(1):e198888. doi: 10.1172/JCI198888. eCollection 2026 Jan 2. Citation on PubMed
  • Valerio CM, Viola LF, Guidorizzi NR, Lima JG, Godoy-Matos AF, Hohl A, Trujilho FR, Dantas JR, de Melo Campos JTA, Zajdenverg L, Muniz RBG, Moreira RO, Fernandes VO, Foss-Freitas MC, Montenegro R Jr. Brazilian expert consensus on the diagnosis, classification, screening for complications and treatment of familial partial lipodystrophy. Diabetol Metab Syndr. 2025 Jun 2;17(1):186. doi: 10.1186/s13098-025-01733-5. Citation on PubMed
  • Vigouroux C, Guenantin AC, Vatier C, Capel E, Le Dour C, Afonso P, Bidault G, Bereziat V, Lascols O, Capeau J, Briand N, Jeru I. Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus. 2018 Jan 1;9(1):235-248. doi: 10.1080/19491034.2018.1456217. Citation on PubMed

The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.